GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Anika Therapeutics Inc (NAS:ANIK) » Definitions » EPS without NRI
中文

Anika Therapeutics (Anika Therapeutics) EPS without NRI

: $-0.73 (TTM As of Dec. 2023)
View and export this data going back to 1993. Start your Free Trial

Anika Therapeutics's earnings per share without non-recurring items for the three months ended in Dec. 2023 was $0.02. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.73.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Anika Therapeutics's EPS without NRI or its related term are showing as below:

During the past 13 years, Anika Therapeutics's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 72.40% per year. The lowest was -65.10% per year. And the median was 0.60% per year.

ANIK's 3-Year EPS without NRI Growth Rate is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 10
* Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.

Anika Therapeutics's EPS (Diluted) for the three months ended in Dec. 2023 was $-4.30. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-5.65.

Anika Therapeutics's EPS (Basic) for the three months ended in Dec. 2023 was $-4.30. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-5.65.


Anika Therapeutics EPS without NRI Historical Data

The historical data trend for Anika Therapeutics's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anika Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.05 0.71 -0.02 -0.49 -0.30

Anika Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.21 -0.36 0.06 -0.45 0.02

Competitive Comparison

For the Medical Instruments & Supplies subindustry, Anika Therapeutics's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anika Therapeutics PE Ratio without NRI Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Anika Therapeutics's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Anika Therapeutics's PE Ratio without NRI falls into.



Anika Therapeutics EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.73

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Anika Therapeutics  (NAS:ANIK) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Anika Therapeutics EPS without NRI Related Terms

Thank you for viewing the detailed overview of Anika Therapeutics's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Anika Therapeutics (Anika Therapeutics) Business Description

Traded in Other Exchanges
Address
32 Wiggins Avenue, Bedford, MA, USA, 01730
Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States.
Executives
Anne Nunes officer: SVP, Chief Operations Officer 32 WIGGINS AVENUE, BEDFORD MA 01730
Gary P Fischetti director 600 TECHNOLOGY PARK DRIVE, 4TH FLOOR, BILLERICA MA 01821
David Colleran officer: EVP, General Counsel, Corp Sec 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Cheryl R Blanchard director C/O ZIMMER, INC., P.O. BOX 708, WARSAW IN 46580
Michael L Levitz officer: EVP, CFO, Treasurer C/O ANALOGIC CORPORATION, 8 CENTENNIAL DRIVE, PEABODY MA 01960
Sheryl L Conley director C/O NEURONETICS, INC., 3222 PHOENIXVILLE PIKE, MALVERN PA 19355
Henneman John B Iii director 311 C ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Raymond J Land director
Stephen Richard director C/O ANIKA THERAPEUTICS, INC., 32 WIGGINS AVENUE, BEDFORD MA 01730
James Loerop officer: EVP Business Development C/O ACLARIS THERAPEUTICS, INC., 640 LEE ROAD, SUITE 200, WAYNE PA 19087
Sylvia Cheung officer: CFO ANIKA THERAPEUTICS, INC., 32 WIGGINS AVENUE, BEDFORD MA 01730
Glenn R. Larsen director 32 WIGGINS AVENUE, BEDFORD MA 01730
Joseph I Bower director 32 WIGGINS AVENUE, BEDFORD MA 01730
Jeffery S Thompson director 1140 HAVENBROOK COURT, SUWANEE GA 30024
Joseph G Darling officer: President 501 MANDALAY AVE., UNIT 409, CLEARWATER BEACH FL 33767